NLA Resources
Knowledge Center
Membership Resources
Join the National Lipid Association, focused on enhancing the science and practice of lipidology to promote optimal cardiometabolic health.
After making your filter selections, please scroll down to see results.
The Young Active Asymptomatic Patient With Very High LDL-C
We present a clinical case and offer Practical Pearls from primary care/Lipid Specialist and cardiology for management of a common scenario, reinforcing the importance of…
Renewed Justification for Triglyceride-Lowering Therapy: Insight from REDUCE-IT and Previous Fibrate Trials
An accumulating body of evidence has implicated hypertriglyceridemia as a treatable risk factor for the prevention of atherosclerotic cardiovascular diseases (ASCVD).(1) Most notably, the Reduction…
Finding Familial Hypercholesterolemia in the Perinatal Period
Familial hypercholesterolemia (FH) is an autosomal codominant genetic disorder of lipoprotein metabolism associated with disproportionately high levels of lowdensity lipoprotein cholesterol (LDL-C) and an increased…
Maximizing Patient-Clinician Engagement: Shared Decision-Making
Cardiovascular disease (CVD) is the leading cause of death worldwide, accounting for nearly 18 million deaths in 2017 with 859,125 of those occurring in the…
The Effects of Testosterone Therapy in Females on Lipid Parameters and Cardiovascular Disease Risk
In a systematic review and meta-analysis of 29 trials with moderate risk of bias, Maraka S. et al summarized the effect of sex hormone therapy…
Case Study: Type 1 Diabetes, Familial Hypercholesterolemia, and Elevated Lipoprotein(a)
Familial hypercholesterolemia (FH) and type 1 diabetes (T1D) are characterized by significant morbidity and premature mortality. Lipoprotein(a) [Lp(a)], an independent cardiovascular disease (CVD) risk factor,…
Motivation from Failure
Imagine the following scenario: Your patient presents for a routine follow-up appointment. As you review the chart you realize the labs, blood pressure, and/or weight…
Statins and Brain Fog: Confusing for Patients, Prescribers, and Me
HMG-CoA reductase inhibitors (statins) were FDA-approved in 1987 and their introduction has revolutionized lipid and cardiovascular (CV) management for the past three decades. Despite this,…